Home Ingredients Sucrosomial® Iron
Women's HealthKidney/Urinary TractGut Health

Sucrosomial® Iron

Evidence Level
Moderate
3 Clinical Trials
5 Documented Benefits
3/5 Evidence Score

Sucrosomial® Iron is a Pharmanutra/Alesco-developed delivery form of ferric pyrophosphate microencapsulated in a phospholipid bilayer plus sucrester matrix. The encapsulation is designed to bypass the gastric environment and the divalent-metal-transporter 1 (DMT1) absorption bottleneck, taking up iron through M-cells and macrophages of the gut-associated lymphoid tissue. This produces high bioavailability with notably lower gastrointestinal distress compared with traditional ferrous-iron salts, and human trials show it is effective for iron-deficiency anemia in chronic kidney disease, inflammatory bowel disease, oncology, and ulcerative colitis populations where conventional oral iron is often poorly tolerated.

Studied Dose Typically 30 mg elemental iron/day in IBD trials (12 weeks); 30 mg/day for several weeks in CKD and ulcerative colitis trials; 30 mg/day alongside darbepoetin in oncology anemia trials.
Active Compound Sucrosomial® Iron — ferric pyrophosphate microencapsulated in a phospholipid bilayer and sucrester matrix (M-cell/macrophage uptake)

Benefits

Iron repletion with low GI distress

Sucrosomial iron supports hemoglobin and iron-status recovery in iron-deficient adults with markedly fewer gastrointestinal complaints than traditional ferrous-iron salts, which is particularly useful for people who cannot tolerate conventional oral iron.

Supported by Trial 1, Trial 3

Iron support in chronic kidney disease

In non-dialysis chronic kidney disease, oral sucrosomial iron has been used to recover iron-deficiency anemia with outcomes that have been compared favorably to intravenous iron in cost-minimization analyses.

Supported by Trial 1, Trial 2

Iron support in inflammatory bowel disease

In adults with inflammatory bowel disease and iron-deficiency anemia, sucrosomial iron has been shown to be safe, well-tolerated, and effective at improving hemoglobin in most patients — a population that often cannot tolerate ferrous sulfate due to gut inflammation.

Supported by Trial 1, Trial 3

Iron support in oncology anemia

In anemic cancer patients receiving darbepoetin alfa during chemotherapy, oral sucrosomial iron has been compared with intravenous iron with favorable hemoglobin response and quality-of-life endpoints in a pilot trial.

Supported by Trial 2

Iron support in ulcerative colitis

In adults with ulcerative colitis and anemia, oral sucrosomial iron has been compared with intravenous ferric carboxymaltose with effectiveness for hemoglobin recovery and good tolerability, supporting oral options in this population.

Supported by Trial 3, Trial 2

Mechanism of action

1

M-cell and macrophage absorption pathway

The sucrosomial matrix protects ferric pyrophosphate from the gastric environment and bypasses DMT1, with iron taken up by M-cells of Peyer's patches and gut-associated macrophages, then released into systemic circulation via transferrin.

2

Reduced free luminal iron

Because iron is encapsulated rather than dissolved in the gut lumen, less free iron is available to interact with mucosa, microbiota, and dietary components — a likely contributor to the lower nausea, constipation, and metallic-taste rates reported in clinical use.

3

Phospholipid-mediated transport

The phospholipid bilayer of the sucrosome is hypothesized to interact with intestinal epithelial membranes and lipid-trafficking pathways, supporting iron transit independently of the saturable DMT1 pathway used by traditional ferrous salts.

Clinical trials

1
Sucrosomial Iron in IBD with Iron-Deficiency Anemia

Pilot study of oral sucrosomial iron (30 mg elemental iron/day) for 12 weeks in adults with inflammatory bowel disease and mild iron-deficiency anemia. Endpoints: hemoglobin, ferritin, tolerability, and gastrointestinal adverse events.

Adults with IBD and mild iron-deficiency anemia. 12 weeks.

Sucrosomial iron was well tolerated with minimal gastrointestinal side effects, and most patients showed increased hemoglobin levels by 12 weeks. Supports the use of sucrosomial iron in IBD where conventional ferrous salts are often poorly tolerated.

2
Sucrosomial Iron in Oncology Anemia

Pilot study comparing oral sucrosomial iron with intravenous iron in anemic cancer patients without iron deficiency who were receiving darbepoetin alfa during chemotherapy. Endpoints: hemoglobin response, transfusion need, safety, quality of life.

Anemic cancer patients on darbepoetin alfa.

Oral sucrosomial iron produced hemoglobin responses and quality-of-life outcomes comparable to intravenous iron, with favorable tolerability. Supports oral sucrosomial iron as an alternative to IV iron in selected oncology anemia patients.

3
Sucrosomial Iron in Ulcerative Colitis

Comparative trial of oral sucrosomial iron versus intravenous ferric carboxymaltose for anemia in patients with ulcerative colitis. Endpoints: hemoglobin recovery, ferritin, tolerability.

Adults with ulcerative colitis and anemia.

Oral sucrosomial iron was as effective as intravenous ferric carboxymaltose for hemoglobin recovery in this population, with good tolerability and a more convenient route of administration. Supports oral sucrosomial iron as a first-line option in ulcerative colitis-related anemia.

Side effects and drug interactions

Common Potential side effects

Mild gastrointestinal discomfort, nausea, or constipation in a minority of users.
Dark stools, which are expected with any iron supplementation.
Rare allergic skin reactions to the encapsulation excipients.
Iron overload risk in people with hereditary hemochromatosis or untreated thalassemia.

Important Drug interactions

Levothyroxine — iron may reduce thyroid hormone absorption; separate doses by 4 hours.
Tetracyclines and fluoroquinolones — iron binds these antibiotics; separate by 2–4 hours.
Proton pump inhibitors and H2 blockers — may reduce iron absorption from non-sucrosomial forms; sucrosomial less affected but caution.
Bisphosphonates and methyldopa — chelation with iron can reduce drug absorption; separate doses.

More Women's Health Ingredients

Cardiovascular
Pycnogenol® (French Maritime Pine Bark)
Pycnogenol® (Horphag Research) is a standardized extract from the bark of French maritime…
Cognitive
Vitamin B6 (Pyridoxine)
Vitamin B6 (pyridoxine) is a water-soluble vitamin essential for amino acid metabolism, ne…
Metabolic Health
Inositol (Myo-Inositol)
Inositol is a naturally occurring sugar alcohol that acts as a secondary messenger in insu…
Mood & Mental Health
Saffron Extract (Crocus sativus)
Saffron is the dried stigmas of Crocus sativus — the most expensive spice in the world by…

Explore Other Ingredients

Cognitive
L-Theanine
L-Theanine, an amino acid primarily found in green tea (Camellia sinensis), is commonly su…
Antioxidant
Curcumin/Turmeric
Curcumin, the primary bioactive compound in turmeric (Curcuma longa), is commonly suppleme…
Antioxidant
Chlorella
Chlorella is a single-celled freshwater green algae rich in chlorophyll, complete protein…

Frequently asked questions about Sucrosomial® Iron

What is the recommended dosage of Sucrosomial® Iron?

The clinically studied dose for Sucrosomial® Iron is Typically 30 mg elemental iron/day in IBD trials (12 weeks); 30 mg/day for several weeks in CKD and ulcerative colitis trials; 30 mg/day alongside darbepoetin in oncology anemia trials.. Always follow product labeling and consult a healthcare provider for personalized dosing recommendations.

What is Sucrosomial® Iron used for?

Sucrosomial® Iron is studied for iron repletion with low gi distress, iron support in chronic kidney disease, iron support in inflammatory bowel disease. Sucrosomial iron supports hemoglobin and iron-status recovery in iron-deficient adults with markedly fewer gastrointestinal complaints than traditional ferrous-iron salts, which is particularly useful for people who cannot tolerate conventional oral …

Are there side effects from taking Sucrosomial® Iron?

Reported potential side effects may include: Mild gastrointestinal discomfort, nausea, or constipation in a minority of users. Dark stools, which are expected with any iron supplementation. Always consult a healthcare provider before starting any new supplement, especially if you have underlying conditions or take medications.

Does Sucrosomial® Iron interact with medications?

Known drug interactions may include: Levothyroxine — iron may reduce thyroid hormone absorption; separate doses by 4 hours. Tetracyclines and fluoroquinolones — iron binds these antibiotics; separate by 2–4 hours. Consult a pharmacist or healthcare provider if you take prescription medications.

Is Sucrosomial® Iron good for women's health?

Yes, Sucrosomial® Iron is researched for Women's Health support. Sucrosomial iron supports hemoglobin and iron-status recovery in iron-deficient adults with markedly fewer gastrointestinal complaints than traditional ferrous-iron salts, which is particularly useful for people who cannot tolerate conventional oral iron.

References(4 citations)

Evidence ratings on NutraSmarts are based on the totality of human clinical research, with emphasis on randomized controlled trials, meta-analyses, and systematic reviews. The references below directly support claims made throughout this page.

  1. Abbati G, Incerti F, Boarini C, Pileri F, Bocchi D, Ventura P, Buzzetti E, Pietrangelo A. Safety and efficacy of sucrosomial iron in inflammatory bowel disease patients with iron deficiency anemia. Intern Emerg Med. 2019;14(3):423-431. doi: 10.1007/s11739-018-1993-9.PubMedUsed to support: Pilot study in IBD patients with mild iron-deficiency anemia; oral sucrosomial iron 30 mg/day for 12 weeks was well tolerated with minimal gastrointestinal side effects and ~86% of patients showed increased hemoglobin. Backs the IBD-specific tolerability and efficacy claim.
  2. Mafodda A, Giuffrida D, Prestifilippo A, Azzarello D, Giannicola R, Mare M, Maisano R. Oral sucrosomial iron versus intravenous iron in anemic cancer patients without iron deficiency receiving darbepoetin alfa: a pilot study. Support Care Cancer. 2017;25(9):2779-2786. doi: 10.1007/s00520-017-3690-z.PubMedUsed to support: Pilot trial in anemic cancer patients on darbepoetin alfa during chemotherapy; oral sucrosomial iron produced hemoglobin responses comparable to IV iron with good tolerability. Backs the oncology-anemia claim.
  3. Bertani L, Tricò D, Zanzi F, Baiano Svizzero G, Coppini F, de Bortoli N, Bellini M, Antonioli L, Blandizzi C, Marchi S. Oral Sucrosomial Iron Is as Effective as Intravenous Ferric Carboxy-Maltose in Treating Anemia in Patients with Ulcerative Colitis. Nutrients. 2021;13(2):608. doi: 10.3390/nu13020608.PubMedUsed to support: Trial in adults with ulcerative colitis and anemia; oral sucrosomial iron was as effective as IV ferric carboxymaltose for hemoglobin recovery with good tolerability. Backs the ulcerative-colitis-specific anemia claim.
  4. Riccio E, Sabbatini M, Capuano I, Pellegrino AM, Petruzzelli LA, Pisani A. Oral Sucrosomial iron versus intravenous iron for recovering iron deficiency anaemia in ND-CKD patients: a cost-minimization analysis. BMC Nephrol. 2020;21(1):57. doi: 10.1186/s12882-020-01716-w.PubMedUsed to support: Cost-minimization analysis of oral sucrosomial iron versus IV iron gluconate in 99 non-dialysis CKD patients with iron-deficiency anemia; oral sucrosomial iron compared favorably to IV iron with substantial cost savings per patient cycle. Backs the chronic-kidney-disease anemia support claim.